21,522 Shares in Blueprint Medicines Corporation (NASDAQ:BPMC) Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,522 shares of the biotechnology company's stock, valued at approximately $1,905,000.

Other large investors also recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter valued at $103,356,000. Norges Bank acquired a new stake in shares of Blueprint Medicines during the fourth quarter valued at $62,028,000. Rock Springs Capital Management LP boosted its stake in shares of Blueprint Medicines by 42.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company's stock valued at $95,672,000 after acquiring an additional 328,123 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after acquiring an additional 316,754 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Blueprint Medicines by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock valued at $495,331,000 after acquiring an additional 291,822 shares during the last quarter.

Insider Buying and Selling

In other news, insider Percy H. Carter sold 1,051 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was sold at an average price of $128.25, for a total value of $134,790.75. Following the sale, the insider owned 53,155 shares of the company's stock, valued at approximately $6,817,128.75. The trade was a 1.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the sale, the insider directly owned 16,944 shares in the company, valued at $1,747,434.72. This represents a 13.97% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,351 shares of company stock worth $1,384,244. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

Shares of BPMC stock remained flat at $129.46 during trading hours on Friday. Blueprint Medicines Corporation has a 1 year low of $73.04 and a 1 year high of $129.65. The stock's 50-day simple moving average is $122.43 and its 200 day simple moving average is $104.28. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.80 and a quick ratio of 2.75. The company has a market cap of $8.36 billion, a price-to-earnings ratio of -52.41 and a beta of 0.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The business had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. Blueprint Medicines's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 EPS. Equities analysts forecast that Blueprint Medicines Corporation will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, May 2nd. Scotiabank downgraded Blueprint Medicines from a "strong-buy" rating to a "sector perform" rating and set a $135.00 target price on the stock. in a research report on Monday, June 2nd. Needham & Company LLC downgraded Blueprint Medicines from a "buy" rating to a "hold" rating and set a $130.00 target price on the stock. in a research report on Monday, June 2nd. UBS Group increased their target price on Blueprint Medicines from $88.00 to $129.00 and gave the stock a "neutral" rating in a research report on Thursday, June 5th. Finally, Wells Fargo & Company downgraded Blueprint Medicines from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $143.00 to $129.00 in a research report on Tuesday, June 17th. Eighteen research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Hold" and a consensus target price of $128.25.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.